Bayer AG

DE

BAYG

Health Care

7.355 ₽

Current price

Buy
7.355 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    501 / 1328

  • Position in country

    404 / 963

  • Return on Assets, %

    -2.5

    -2.7

  • Net income margin, %

    11.3

    2.8

  • EBITDA margin, %

    25.7

    10.8

  • Debt to Equity, %

    136.6

    19.2

  • Intangible assets and goodwill, %

    47.8

    3.6

  • Revenue CAGR 3Y, %

    4.7

    8.5

  • Total Equity change 1Y, %

    -12.5

    0

  • Revenue Y, % chg

    -3.5

    0.5

  • P/BV

    0.8

    1.5

  • P/S

    0.5

    2.3

  • EV/S

    1.2

    2.4

  • EV/EBITDA

    3.2

    7.4

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    302.3

    51.3

  • Forward P/E

    2.4

    15.6

  • Dividend Yield, %

    0.4

    1.7

  • Forward Dividend Yield, %

    25.5

    0.2

  • Expected dividend per share

    1.8

    0

  • Dividend Ex Date

    2024-04-29

Get an analytical review of this company

Competitors

Ranks

  • Novo Nordisk A/S

    00%

  • AstraZeneca PLC

    00%

  • Bayer AG

    00%

  • Eli Lilly and Co

    00%

  • Roche Holding AG

    00%

  • Merck KGaA

    00%

  • Dermapharm Holding SE

    00%

  • Novartis AG

    00%

  • Johnson & Johnson

    00%

  • Merck & Co Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Germany

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    28408.9

  • Ticker

    BAYRY.PK

  • ISIN

    US0727303028

  • IPO date

    1997-11-28

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-03-05

  • Date fact. publication of reports

    2023-12-31

Company Description

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non